MicroPort® Products Showcases at China Indigenous Brand Expo

Shanghai, China—The China Indigenous Brand Expo was held in Shanghai Exhibition Center from May 10-12, 2021. The event kicked off with the theme of “Chinese brand, world sharing”, “Focusing on Dual Circulation and Leading New Consumption”. As a representative brand of high-end medical devices in China, MicroPort® Scientific Corporation (“MicroPort®”) attracted wide attention at the expo by showcasing seven independently developed products: the Firehawk® Rapamycin Target Eluting Coronary Stent System, Rega® Family Implantable Pacemakers, SoSuperiorTM Medial-Stabilized Total Knee Replacement Systems, VitaFlow® Transcatheter Aortic Valve and Delivery System, Tubridge® Vascular Reconstruction Device, Castor® Branched Aortic Stent-Graft System and Columbus® 3D EP Navigation System.

As a key exhibitor from Shanghai, MicroPort® showcased its innovative products and total medical solutions covering various fields such as cardiovascular and structural heart disease, electrophysiology and cardiac rhythm management system, orthopedics, aorta and peripheral vascular disease, and neuro intervention. The new-generation home-grown Firehawk®️ stent is considered by industry experts to have solved a major problem that has been troubling the field of cardiovascular intervention for over a decade. In 2018, study results of the MicroPort® Firehawk Stent System in a large-scale clinical trial in Europe was published in full text under The Lancet, the world's top medical journal, which is the first time that a Chinese medical device was featured in the journal in nearly 200 years since its first publication, marking a follower-to-leader transformation for MicroPort® in the field of coronary stents. After gaining a strong foothold in domestic and international markets in the field of coronary stents, MicroPort® entered the field of cardiac radiofrequency ablation and developed the first domestic 3D EP Navigation System based on magneto-electric dual positioning, with the aim of providing a total solution for heart diseases. Shortly afterwards, MicroPort® rolled out the first domestic pacemaker with world-class quality, which better suits the lean body type of Chinese patients with a 10- to 12-year lifespan, making the domestic pacemaker available to more and more Chinese patients. In the era of minimally invasive surgery for structural heart disease, MicroPort® has pioneered the technical pathway to heart valve replacement by interventional therapy. Its subsidiary, CardioFlow Medtech, which focuses on the innovative development and commercialization of transcatheter and surgical solutions in the field of heart valve disease, has been listed on the Hong Kong Stock Exchange in February 2021. In the field of aorta and peripheral vascular disease, MicroPort® Endovastec has become one of the first companies to be listed on the STAR board, offering a total solution in this segment with five home-grown products entering the “Green Path” for innovative medical devices. In the field of neuro intervention, MicroPort® NeuroTech aims to be a “total solution provider for cerebral apoplexy” and has developed numerous innovative products that are the first and only in China. In the field of orthopedics, the Medial-Pivot Knee System by MicroPort® Orthopedics has been used in more than 720,000 implantation cases worldwide, with proven high prosthesis retention rate (98.8%) and patient satisfaction (95%) from more than two decades of clinical use.

For more than two decades since its establishment, MicroPort® has been focusing on independent innovation and has marketed more than 300 products to over 10,000 hospitals in over 80 countries and regions, covering major markets in the Asia Pacific, Europe and the Americas. Worldwide, one MicroPort® product is used every six seconds to save lives, improve quality of life, or help usher in new life. With the motto of “helping hundreds of millions of people around the world to live a healthy life beyond 115 years”, MicroPort® will continue to fulfill its vision of building a brand that belongs to both patients and doctors and to promote global awareness of the MicroPort® brand as a contribution to the advancement of the Chinese Brands strategy.